BeiGene, Mirati Enter Exclusive License Agreement

For the development, manufacturing and commercialization of Mirati’s sitravatinib

BeiGene, Ltd. and Mirati Therapeutics have entered an exclusive license agreement for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia, Australia, and New Zealand.    Mirati will retain exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world.   Sitravatinib is an investigational tyrosine kinase inhibitor that has demonstrated potent inhibition of receptor tyrosine kinases (RTKs), includin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters